| Document |
Document Title |
|
WO/2015/143653A1 |
The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of...
|
|
WO/2015/143652A1 |
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, ...
|
|
WO/2015/138869A1 |
The present disclosure provides new materials that combine the advantages of well-defined polymeric starting materials and the convenience of surface modification by physical methods into one package and, thus, offers a general and power...
|
|
WO/2015/125085A1 |
The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are G...
|
|
WO/2015/108136A1 |
The present invention provides: a novel α-substituted glycinamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the compound or the pharmacologically acceptable salt; and a use of the...
|
|
WO/2015/107541A1 |
The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use ...
|
|
WO/2015/104433A1 |
The invention relates to benzo[c][1,2,5]oxadiazole derivatives, and the use thereof as antibiotics and in particular for the treatment and/or prevention of diseases caused by bacteria, in particular of diseases caused by Helicobacter.
|
|
WO/2015/101958A2 |
The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or d...
|
|
WO/2015/100441A1 |
Disclosed are conjugated polymers having desirable properties as semiconducting materials. Such polymers are cheap and easy to synthesize, and can exhibit good solubility and great solution processibility, and that enable highly efficien...
|
|
WO/2015/094930A1 |
In its many embodiments, the present invention provides certain C-6 spirocarbocyclic iminothiadiazine compounds, including compounds Formula (I): or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said ta...
|
|
WO/2015/074180A1 |
Disclosed is a method for preparing thiadiazolylamide compounds. 2-sulfinyl-5-(trifluoromethyl)-1,3,4-thiadiazole (II) and 2-sulfuryl--5- (trifluoromethyl)-1,3,4-thiadiazole (II') are mixed in mass ratio of 99:1-1:99 as mixed raw materia...
|
|
WO/2015/033303A1 |
The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The i...
|
|
WO/2015/033301A1 |
The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeut...
|
|
WO/2015/033299A1 |
The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeuti...
|
|
WO/2015/031109A1 |
Compounds, or pharmaceutically acceptable salts or esters thereof, having a structure of: wherein each of R1-R5 is individually selected from H, halogen, optionally substituted alkyl, optionally substituted alkoxy, nitro, sulfonamide, hy...
|
|
WO/2015/016442A1 |
The present invention relates to a novel phenylthiazole-based hydroxamic acid compound and an anti-cancer composition containing same as an active ingredient. A hydroxamic acid compound according to the present invention exhibits anti-ca...
|
|
WO/2015/006100A1 |
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
|
|
WO/2014/181137A1 |
The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.
|
|
WO/2014/173904A1 |
The present invention relates to compounds of formula (I) and their uses. In particular, though not exclusively, it concerns heterocyclic compounds that inhibit the biogenesis of adhesive pili in Gram- negative bacteria, and their use in...
|
|
WO/2014/170793A1 |
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new s...
|
|
WO/2014/161516A1 |
A substituted diazole of genera l formula (1) wherein X is 0 or S; R is selected from the group consisting of: H, NH2-, C1-C11n alkyl, cyclohexyl-, benzyl-, phenyl-, pyridyl- or phenyl- substituted, in positions 2, 3, 4 or 5, by one or m...
|
|
WO/2014/157653A1 |
The present invention addresses the problem of providing an efficient process for preparing important intermediate compounds (1) and (1a) for the production of FXa inhibitors (X) and (X-a). The present invention pertains to: a process wh...
|
|
WO/2014/156553A1 |
A purpose of the present invention is to provide a new disulfide compound with excellent compatibility toward polymers containing fluorine and solutions containing fluorine. The compound of the present invention is a compound expressed b...
|
|
WO/2014/157497A1 |
An organic photoelectric conversion element which is provided with a first electrode, a photoelectric conversion layer that contains a compound represented by formula (I), and a second electrode; an organic thin film solar cell; a compos...
|
|
WO/2014/150340A1 |
In its many embodiments, the present invention provides provides certain S-imino-S-oxo iminothiadiazine compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of sai...
|
|
WO/2014/146275A1 |
The present invention relates to a method for synthesizing a thiadiazole sulfoxide compound. Steps thereof comprise: thiadiazole thioether reacting in an organic solvent or mixed liquor of an organic solvent and water, by using a specifi...
|
|
WO/2014/152588A1 |
Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
|
|
WO/2014/140059A1 |
Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, X5, X6, Y, Z, G, R1a, R2a, R1b, R2b, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the co...
|
|
WO/2014/138833A1 |
The present invention describes new compounds for binding and/or inhibiting enzymes in microorganisms. In one embodiment, the compounds of the present invention are used to inhibit the 2-trans-enoyl-ACP (CoA) reductase enzyme in microorg...
|
|
WO/2014/136099A1 |
The present invention relates to a novel process of making ixabepilone, ixabepilone derivatives and analogues, and intermediates thereof.
|
|
WO/2014/123203A1 |
Provided is a compound having PTP-1B inhibitory activity that is excellent as a drug, or a pharmaceutically acceptable salt thereof. A compound represented by general formula (I) (in the formula, each symbol means the same as in the spec...
|
|
WO/2014/121439A1 |
A synthesis method of 2-[(5-(trifluoromethyl)-1,3,4-thiadiazolyl-2-yl)-oxy]amide derivative (I). The method comprises the following step: in a solvent insoluble with water, 2-sulphinyl-5-trifluoromethyl-thiadiazole (II) and amide (III) r...
|
|
WO/2014/108791A1 |
The present invention relates to stable ready to use injectable liquid composition of chlorothiazide or its pharmaceutically acceptable salts.
|
|
WO/2014/099768A1 |
In its many embodiments, the present invention provides certain C2-ring-substituted thiadiazine compounds, including compounds Formula (I): (structure represented) or tautomers thereof, and pharmaceutically acceptable salts of said compo...
|
|
WO/2014/093190A1 |
In its many embodiments, the present invention provides certain C2-ring-substituted iminothiadiazine compounds, or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers. The novel compounds of th...
|
|
WO/2014/092082A1 |
The purpose of the present invention is to provide a novel mercapto compound which has superior affinity to fluorine-containing polymers and fluorine-containing solvents. This compound is represented by formula (1) (in formula (1), R1 an...
|
|
WO/2014/087298A1 |
The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or –CR0 --, where R0 is hydrogen, C1 -C6 linear or branched chain alkyl, etc., Z is –CRe --, or, –N--, where Re is hydrogen, C1 -C6 linear or branched...
|
|
WO/2014/084410A1 |
The present invention provides a compound having an excellent efficacy for controlling weeds. A cyclohexanone compound of formula (I): wherein n is an integer of any one of 1 to 5; R1 represents a hydrogen atom or a methyl group; R2 and ...
|
|
WO/2014/084405A1 |
A method for reacting a compound represented by formula (A) and a compound represented by formula (B) in a solvent and producing a halogen compound represented by formula (C). (In formula (A), Y1 represents a sulfur atom or the like, X1 ...
|
|
WO/2014/078971A1 |
This technology comprises compounds derived from 1,3,4-thiadiazole alkylamides and chalcone, which inhibit the activation of the TRPV-1 receptor by means of capsaicin and temperature. Said compounds have a strong antagonist activity in t...
|
|
WO/2014/081925A1 |
Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
|
|
WO/2014/063199A1 |
Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in...
|
|
WO/2014/051939A1 |
The present invention provides novel phenicol derivatives of formula (I), their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.
|
|
WO/2014/049107A1 |
The present invention concerns compounds of general formula (I): (I) in which Y and Z are chosen from CH and N; T is chosen from CO or SO2; n is 1 to 3; R1 represents a group chosen, for example, from C1-C3 alkyl chains unsubstituted or ...
|
|
WO/2014/031732A2 |
Provided are compositions and methods for treating a condition or disorder mediated by fascin activity in a subject in need thereof which method comprises administering to the subject a therapeutically effective amount of at least one co...
|
|
WO/2014/006402A1 |
The disclosures herein relate to novel compounds of formula wherein W, X and Y1, Y2, Y3 and Y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disor...
|
|
WO/2014/003124A1 |
The compound represented by formula (1) or a salt thereof has a collagen production-inhibiting effect, and is thus useful for use in the prevention, treatment, or the like of diseases associated with overproduction of collagen such as pu...
|
|
WO/2013/189481A1 |
The invention relates to 1,2,4-thiadiazinane-1,1-dioxide derivatives, to a method for producing same, to electrolytes that contain such derivatives, and to the use of the derivatives, in particular as an electrolyte additive for lithium ...
|
|
WO/2013/172171A1 |
A cyclic carbodiimide compound represented by formulas (O-1) or (O-2) can be used for producing a polyester film that does not contain isocyanates with a small molecular weight and that has excellent thickness uniformity without any thic...
|
|
WO/2013/167994A1 |
Provided are the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compoun...
|
